Table 1 Relationship between replication factor C subunit 2 (RFC2) immunoreactivity and clinicopathological findings in human prostate cancer patients (n = 103).

	RFC2 IR score (N = 103)
	Low IR < 4 (N = 62)	High IR ≥ 4 (N = 41)	P-value
Age (y)	67.1 ± 5.9	66.0 ± 6.3	0.6904
Serum PSA level
PSA < 10 ng/mL	33	20	0.8399
PSA ≥ 10 ng/mL	29	20
Pathological Gleason score (pGS)
pGS < 8	48	13	< 0.0001
pGS ≥ 8	14	28
Pathological T stage
pT < 3b	53	15	< 0.0001
pT ≥ 3b	9	26
Pathological N stage
pN = 0	58	31	0.0164
pN = 1	4	10

Immunoreactivity (IR) score (0, 2–8) was obtained as the sum of the intensity and the area of IR. Intensity (0, none; 1, weak; 2, moderate; and 3, strong), Proportion (0, none; 1, < 1/100; 2, 1/100 to 1/10; 3, 1/10 to 1/3; 4, 1/3 to 2/3; and 5, > 2/3). Fisher’s exact test and Mann–Whitney U test were performed to determine P-value. P-value < 0.05 was considered to be statistically significant. IR scores of 0‐4 and 5–8 were defined as low and high IR, respectively. PSA prostate specific antigen. Note that serum PSA was not measured in one patient. Significant values are in bold.

Quick links

Search